DOCSLIB.ORG

Back Matter (PDF)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Back Matter (PDF) INDEX Volume 172, March-April 1970 Acetazolamide, influence on anion secretion into adrenergic, in rabbit aortic strips, interactions cerebrospinal fluid, 197 between potentiating agents of, 320 Acetylcholine(s) retention in rat heart, effect of bretylium on, 282 effect on adrenal catecholamine secretion, 69 syrnpathomimetic, mephentermine and, evalua- halogeno-, cholinergic activities of, 351 tion of vasodilation produced by, 297 nicotine and, comparison of effects on cycle Amino acids, y-aminobutyric acid and, actions on length and action potentials of guinea-pig mammalian autonomic ganglia, 384 atria, 255 ‘y-Aminobutyric acid, related amino acids and, Acetylsalicylic acid, combination with other actions on mammalian autonomic ganglia, 384 drugs, effects on inflammation induced by 7-Amino g-hydroxybutyric acid, effects on main- carrageenan, 423 malian autonoinic ganglia, 384 Acidosis, effects on chronotropic responses, nor- 3-Amino-1-propanesulfonic acid, effects on mam- epinephrine storage and release in isolated malian autonomic ganglia, 384 guinea-pig atria, 289 Amitriptyline, inhibition of metabolism of gua- Adipose tissue, of cattle, sheep, goats and swine, nethidine and related agents by hepatic mi- concentrations of thiopental in, 128 crosomes by, 108 Adrenalectomy, influence on nicotine-induced in- Amphetamine hibition of contractile activity in stomach effect on heart force in dogs, 297 and duodenum of dog, 377 retention in rat heart after bretylium, 282 Adrenal glands d-Amphetamine, potentiation of jumping activity effects of splanchnic nerve stimulation and induced by sodium 5-(1 ,3-dimethylbutyl)-5- cholinergic agents on secretion of catechola- ethyl barbiturate, 170 mines by, 69 Anesthesia release of catecholamines in response to nico- produced by thiopental in cattle, sheep, goats tine, 377 and swine, 128 Adrenergic amines, in rabbit aortic strips, inter- spinal, influence on nicotine-induced inhibition actions between potentiating agents of, 320 of contractile activity in stomach and duo- Adrenergic blockade denum of dog, 377 alpha and beta, and inotropic response to phen- Anesthetics ylephrine, 274 local, effects of pH gradients on action of pro- beta, of chronotropic effects of nicotine and caine and lidocaine in intact and desheathed norepinephrine in guinea-pig atria, 255 sciatic nerves, 1 effect of phentolamine on responses of normal, local, effects of pH gradients on uptake and dis- denervated and decentralized cat nictitating tribution of C’4-procaine and lidocaine in membrane to methoxamine and norepineph- intact and desheathed sciatic nerve trunks, 18 rine, 91 Anoxia, effect on release of norepinephrine from Adrenergic blocking drugs, beta, reduction of spleen, 342 jumping activity induced by sodium 5-(1,3- Antihistaminee, lack of influence on mephenter- dimethylbutyl)-5-ethyl barbiturate, 170 mine-induced vasodilation in dogs, 297 Adrenergic nerves, release of norepinephrine from Antimalarial drugs, chloroquine diphosphate and isolated rat iris by field stimulation, 332 RP-12278, neuromuscular blocking properties Adrenergic neurons, blockade by guanethidine of, 44 and related agents and antagonism by drugs, Aortic smooth muscle, comparison of retentions of 100 methoxamine and norepinephrine in, 91 AHR-0602, inhibition of contractile activity in Aortic strips stomach and duodenum of dog, 377 rabbit, antagonism of phentolamine against -Alanine, effects on mammalian autonomic gan. glia, 384 exogenously administered and endogenously Alpha adrenergic blockade, lack of effect on mo- released norepinephrine in, 310 tropic action of phenylephrine on rabbit atria, rabbit, interactions between potentiating agents 274 of adrenergic amines in, 320 Amine(s) Artery, pulmonary, main, isolated, rabbit, release 427 428 DmEx of H2-norepinephrine in relation to muscle tive inhibition by norepinephrine, guanethi- contraction in, 62 dine, debrisoquin, bretylium, tyramine, me- Askari, A. and Rae, S. N. : Drugs affecting sodium taraminob and desipramine, 100 transport in human erythrocyte ghosts, 211 Bevan, J. A., see Su, C., 62 Aspirin, combination with other drugs, effects on Bianchi, C. P. inflammation induced by carrageenan, 423 see Strobel, G. E., 1, 18 Atria see Suarez-Kurtz, G., 33 guinea-pig and cat, rate and contractile force, Bigger, J. T., Jr. and Mandel, W. J. : Effect of effect of gallamine on, 266 lidocaine on conduction in canine Purkinje guinea-pig, electrically driven, biphasic effect fibers and at the ventricular muscle-Purkinje of nicotine on action potential repolarization fiber junction, 239 in, 255 Bis [(chloro-7’ ‘-quinolyl-4”)amino-2’-propylj-1 , 4- guinea-pig, isolated, effects of acidosis on chro- piperazine (RP-12278), antimalarial agent, notropic responses, norepinephrine storage neuromuscular blocking properties of, 44 and release in, 289 Bladder, toad, effect of bendroflumethiazide on rabbit, blockade of inotropic action of phenyl- sodium transport and metabolism in, 203 ephrine by bretylium or cocaine in, 274 Blockade Atropine adrenergic, effect of phentolamine on responses and responses of denervated cat nictitating of normal, denervated and decentralized cat membrane , 77 nictitating membrane to methoxamine and blockade of effects of acetylcholine and nicotine norepinephrine, 91 in guinea-pig atria, 255 selective, of adrenergic neurons by guanethi- failure to inhibit positive inotropic response to dine and related agents, antagonism by drugs, gallamine, 266 100 lack of influence on mephentermine-induced Blood flow, effects of mephentermine and certain vasodilation in dogs, 297 other sympathomimetic amines on femoral, Autonomic ganglia, mammalian, actions of -y-ami- renal and superior mesenteric arteries in dogs, nobutyric acid and related amino acids on, 384 297 Azzaro, A. J., see Peach, M. J., 289 Boerth, R. C., Ryan, M. J. and Brody, M. J.: Pharmacologic blockade of reflex vasodilata- Barbiturate(s) tion : Effects on postulated neurohumoral in rhesus monkeys, development of tolerance to mechanisms, 52 and physical dependence on, 163 Brain sodium 5-(1 ,3-dimethylbutyl)-5-ethyl, jumping catecholamines synthesized from circulating activity induced by, role of sympathetic H’-tyrosine, daily rhythm in accumulation nervous system, 170 of, 416 Basal metabolism, effect of dioxoisoquinoline-4- dopamine levels in relation to pharmacologic carboxanilides on, 138 actions of L-dopa, 406 Bass, P., see Carlson, G. M., 367, 377 levels, of sodium 5-(1 ,3-dimethylbutyl) -5-ethyl Behavior, punished and unpunished, in pigeon, barbiturate, 170 effects of some benzodiazepines on, 397 of cattle, sheep, goats and swine, concentrations Bendroflumethiazide, effect on sodium transport of thiopental in, 128 and metabolism in toad bladder, 203 Bretylium Benzodiazepines blockade of release of H’-norepinephrine from effects on punished and unpunished behavior arterial strips, 62 in pigeon, 397 cocaine or, blockade of cardiac action of phen- lack of effect in inhibiting jumping activity in- ylephrine by, 274 dueed by sodium 5-(1 ,3-dimethylbutyl)-5- competitive inhibition of uptake of H1-beth- ethyl barbiturate, 170 anidine by heart slices, 100 Beta adrenergic blockade decreased potentiation of norepinephrine re- blockade of inotropic action of phenylephrine on spouses by cocaine after, 320 rabbit atria, 274 effect on amine retention in rat heart, 282 of chronotropic effects of nicotine and norepi- influence on responses of cat nictitating mem- nephrine in guinea-pig atria, 255 brane, 77 Beta adrenergic blocking drugs, reduction of jumping activity induced by sodium 5-(1,3- Broder, L. E., see Maren, T. H., 197 dimethylbutyl).5-ethyl barbiturate, 170 Brodie, B. B., see Koppanyi, T., 170 H.Bethanidine, uptake by heart slices, competi- Brody, M. J., see Boerth, R. C., 52 INDEX 429 Bromoacetylcholine, muscarinic and nicotinic -induced inhibition of contractile activity in activities of, 351 stomach and duodenum of dog, 367 Brown, B. R., Jr. and Crout, J. R. : The sym- potentiation of effects on rabbit aortic strips pathomimetic effect of gallamine on the heart, after inhibition of catechol-O-methyltraus 266 ferase with 4-tropolone acetamide, 320 BW 684-induced vasodilation in dogs, 297 release from spleen, effects of metabolic inhibi- tom on, 342 Calcium release resulting from administration of nico- influence on contracture produced by RP-12278, tine in dog, 377 44 retention in rat heart after bretylium, 282 inhibition of release of norepinephrine from iso- Catechol-Omethyltransfer, inhibition by lated rat iris by field stimulation in absence 4-tropolone acetamide in rabbit aortic strips, of, 332 320 Caidwell, R. W. and Goldberg, L. I. : An evalua- Cavanaugh, J. H., see Mitchell, J. R., 108 tion of the vasodilation produced by mephen- Cells, epithelial, effect of bendroflumethiazide on termine and certain other sympathomimetic sodium transport and metabolism in toad amines, 297 bladder, 203 Carbon dioxide, entry from blood into cerebro- Central nervous system, potentiation and inhibi- spinal fluid before and after inhibition of tion of some central actions of L-dopa by de- carbonic anhydrase, 197 carboxylase inhibitors, 406 Carbonic anhydrase, role in anion secretion into Cerebrospinal fluid cerebrospinal fluid, 197 in cattle, sheep, goats and swine, concentra. Cardiac glycosides tions of thiopental in, 128 effect on interaction of Ca with mitochondria, role of carbonic anhydrase in anion secretion 180 into, 197 six, effects on transmembrane potential and Chang, Y.-H., see Wiseman, E. H., 138 contractile characteristics
Load more

Recommended publications
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Impact of Pharmacogenetic Polymorphisms
    Biotransformation of the Analgesic-Antipyretic Drugs Metamizole and Aminopyrine by Genetically Polymorphic Enzymes Von der Fakultät für Lebenswissenschaften der Technischen Universität Carolo-Wilhelmina zu Braunschweig zur Erlangung des Grades eines Doktors der Naturwissenschaften ( Dr. rer. nat.) genehmigte D i s s e r t a t i o n von Salem Omran Ali Abdalla aus Sokna, Libyen 1. Referent: Professor Dr. Ingo Rustenbeck 2. Referent: Professor Dr. Jürgen Brockmöller eingereicht am: 29. Juni 2007 mündliche Prüfung (Disputation) am: 27. September 2007 Druckjahr 2007 The work described here was performed in the period from July 2002 to April 2007 at the Department of Clinical Pharmacology, Georg-August University, Göttingen To my parents And my children Omran and Raian Table of Contents TABLE OF CONTENTS TABLE OF CONTENTS.......................................................................................................................................I LIST OF ABBREVIATIONS............................................................................................................................ III 1 INTRODUCTION ....................................................................................................................................... 1 1.1 DRUG METABOLISM .............................................................................................................................. 1 1.1.1 Specific reactions in drugs metabolism ........................................................................................... 1 1.2
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,080,578 B2 Liggett Et Al
    USO08080578B2 (12) United States Patent (10) Patent No.: US 8,080,578 B2 Liggett et al. (45) Date of Patent: *Dec. 20, 2011 (54) METHODS FOR TREATMENT WITH 5,998.458. A 12/1999 Bristow ........................ 514,392 BUCNDOLOL BASED ON GENETIC 6,004,744. A 12/1999 Goelet et al. ...... 435/5 6,013,431 A 1/2000 Söderlund et al. 435/5 TARGETING 6,156,503 A 12/2000 Drazen et al. ..... ... 435/6 6,221,851 B1 4/2001 Feldman ... 51446 (75) Inventors: Stephen B. Liggett, Clarksville, MD 6,316,188 B1 1 1/2001 Yan et al. .......................... 435/6 6,365,618 B1 4/2002 Swartz ... 514,411 (US); Michael Bristow, Englewood, CO 6,498,009 B1 12/2002 Liggett ............................. 435/6 (US) 6,566,101 B1 5/2003 Shuber et al. 435,912 6,586,183 B2 7/2003 Drysdale et al. .................. 435/6 (73) Assignee: The Regents of the University of 6,784, 177 B2 8/2004 Cohn et al. 514,248 Colorado, a body corporate, Denver, 6,797.472 B1 9/2004 Liggett ......... ... 435/6 6,821,724 B1 1 1/2004 Mittman et al. ... 435/6 CO (US) 6,861.217 B1 3/2005 Liggett ......... ... 435/6 7,041,810 B2 5/2006 Small et al. ... ... 435/6 (*) Notice: Subject to any disclaimer, the term of this 7, 195,873 B2 3/2007 Fligheddu et al. ... 435/6 patent is extended or adjusted under 35 7,211,386 B2 5/2007 Small et al. ....... ... 435/6 7,229,756 B1 6/2007 Small et al.
    [Show full text]
  • Long Acting, Reversible Veterinary Sedative and Analgesic And
    University of Kentucky UKnowledge Veterinary Science Faculty Patents Veterinary Science 7-11-2006 Long Acting, Reversible Veterinary Sedative and Analgesic and Method of Use Thomas Tobin University of Kentucky, [email protected] Right click to open a feedback form in a new tab to let us know how this document benefits oy u. Follow this and additional works at: https://uknowledge.uky.edu/gluck_patents Part of the Veterinary Medicine Commons Recommended Citation Tobin, Thomas, "Long Acting, Reversible Veterinary Sedative and Analgesic and Method of Use" (2006). Veterinary Science Faculty Patents. 14. https://uknowledge.uky.edu/gluck_patents/14 This Patent is brought to you for free and open access by the Veterinary Science at UKnowledge. It has been accepted for inclusion in Veterinary Science Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact [email protected]. US007074834B2 (12) United States Patent (10) Patent N0.: US 7,074,834 B2 Tobin (45) Date of Patent: Jul. 11, 2006 (54) LONG ACTING, REVERSIBLE VETERINARY 4,742,054 A 5/1988 Naftchi SEDATIVE AND ANALGESIC AND METHOD 4,950,648 A 8/1990 Raddatz et a1. OF USE 5,635,204 A * 6/1997 GevirtZ et a1. ............ .. 424/449 5,942,241 A 8/1999 Chasin et a1. (75) Inventor: Thomas Tobin, Lexington, KY (US) 5,958,933 A 9/1999 Naftchi (73) Assignee: University of Kentucky Foundation, OTHER PUBLICATIONS Lexington, KY (US) MEDLINE AN 20000025586, Veveris et al, Brit. J. Pharmacol, 128 (5), 1089-97, Nov. 1999, abstract.* ( * ) Notice: Subject to any disclaimer, the term of this Veterinary Pharmacology and Therapeutics, Adams, pp.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Table of Antihypertensive Drugs
    Chapter 14 Table of Antihypertensive Drugs F. GROSS and J. B. LUTH The following tables give information about the most important drugs used today in the treatment of high blood pressure. These lists do not in any way aim for completeness, in particular with respect to brand names, which are much more numerous for several of the mentioned products. The usual forms of adminis­ tration and average dosages are included, but various other schemes are also recommended for some drugs in some countries. What is said for the single entities with respect to completeness holds true even more for the fixed combinations, of which only a fraction of those marketed in a number or'countries has been included. Some examples of the combinations that make sense to the authors have been mentioned; many have been omitted; however, deletion does not mean in all cases - but it does in some - that the combi­ nation is considered useless. If a barbiturate is added to reserpine and a diuretic, it is difficult to ascribe to the new combination an improved effect on the high blood pressure. Quite a few more examples could be given, where the addition of a further ingredient to the basic combination of reserpine and a diuretic is nothing but the mixing in of a special flavor, and not of an antihypertensive component. Some of the readers may also feel that too many drugs and combinations have been listed, and they may never have heard the names of quite a few of them. Despite the incompleteness of the list, it gives an impression of the huge variety of pre­ parations, which will further increase with the growing number of /J-adrenergic blockers and their combinations with other drugs.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • 2021 Equine Prohibited Substances List
    2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s). Prohibited Substances that are identified as Specified Substances in the List below should not in any way be considered less important or less dangerous than other Prohibited Substances. Rather, they are simply substances which are more likely to have been ingested by Horses for a purpose other than the enhancement of sport performance, for example, through a contaminated food substance. LISTED AS SUBSTANCE ACTIVITY BANNED 1-androsterone Anabolic BANNED 3β-Hydroxy-5α-androstan-17-one Anabolic BANNED 4-chlorometatandienone Anabolic BANNED 5α-Androst-2-ene-17one Anabolic BANNED 5α-Androstane-3α, 17α-diol Anabolic BANNED 5α-Androstane-3α, 17β-diol Anabolic BANNED 5α-Androstane-3β, 17α-diol Anabolic BANNED 5α-Androstane-3β, 17β-diol Anabolic BANNED 5β-Androstane-3α, 17β-diol Anabolic BANNED 7α-Hydroxy-DHEA Anabolic BANNED 7β-Hydroxy-DHEA Anabolic BANNED 7-Keto-DHEA Anabolic CONTROLLED 17-Alpha-Hydroxy Progesterone Hormone FEMALES BANNED 17-Alpha-Hydroxy Progesterone Anabolic MALES BANNED 19-Norandrosterone Anabolic BANNED 19-Noretiocholanolone Anabolic BANNED 20-Hydroxyecdysone Anabolic BANNED Δ1-Testosterone Anabolic BANNED Acebutolol Beta blocker BANNED Acefylline Bronchodilator BANNED Acemetacin Non-steroidal anti-inflammatory drug BANNED Acenocoumarol Anticoagulant CONTROLLED Acepromazine Sedative BANNED Acetanilid Analgesic/antipyretic CONTROLLED Acetazolamide Carbonic Anhydrase Inhibitor BANNED Acetohexamide Pancreatic stimulant CONTROLLED Acetominophen (Paracetamol) Analgesic BANNED Acetophenazine Antipsychotic BANNED Acetophenetidin (Phenacetin) Analgesic BANNED Acetylmorphine Narcotic BANNED Adinazolam Anxiolytic BANNED Adiphenine Antispasmodic BANNED Adrafinil Stimulant 1 December 2020, Lausanne, Switzerland 2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s).
    [Show full text]
  • Rubidomycin in Acute Leukaemia Foods
    3 June 1967 Leading Articles BRnITH 587 sympathetic efferent function should be given. These com- pathetic blocking agents will give better results than a single prise the ganglion-blocking agents, of which only mecamyl- one.'4 Good results depend to a great extent on the care with amine and pempidine are now used in any quantity, methyl- which the regimen is managed: this is usually more impor- Br Med J: first published as 10.1136/bmj.2.5552.587 on 3 June 1967. Downloaded from dopa, and the drugs which block sympathetic fibres at the tant than the initial choice of drug. neuro-effector junction-bretylium, guanethidine, bethan- idine, guanoxan, guanoclor, and debrisoquine. Pargyline has an effect similar to these drugs on arterial pressure,' but should not usually be prescribed for the maintenance treat- ment of hypertensive patients because it is a monoamine- oxidase inhibitor, and patients receiving drugs of this type may suffer dangerous reactions after some other drugs or Rubidomycin in Acute Leukaemia foods. The ganglion-blocking drugs affect parasympathetic as well as sympathetic functions and thus may cause addi- Rubidomycin is the first antibiotic to show therapeutic effect tional side-effects. Few people would now consider them the in management of acute leukaemia in man. It is produced first choice for the treatment of severe hypertension, though from a strain of Streptomyces coeruleorubidus, and it is active they may be very useful if other drugs fail. Bretylium has in all forms of acute leukaemia. J. Bernard and his now fallen into disfavour because many patients become colleagues,' in an extensive clinical trial, have found it useful tolerant of its hypotensive effects.
    [Show full text]
  • Isolation of an Endogenous Clonidine-Displacing Substance from Rat Brain
    Volume 170, number 2 FEBS 1474 May 1984 Isolation of an endogenous clonidine-displacing substance from rat brain Daphne Atlas and Yigal Burstein* Department of Biological Chemistry, Institute of Life Sciences, The Hebrew University of Jerusalem, 91904 Jerusalem and *Department of Organic Chemistry, The Weizmann Institute of Science, 76100 Rehovot, Israel Received 9 April 1984 An endogenous substance which specifically displaces clonidine, yohimbine and rauwolscine from rat brain cyz-adrenergic receptors, has been isolated. The new compound, designed clonidine-displacing- substance (CDS), has been partially purified by ion exchange chromatography, zone electrophoresis and high performance liquid chromatography (HPLC). CDS binds specifically to cYz-adrenergic receptors by competing with either cuz-adrenergic agonists or cYz-antagonists, but has no effect on the specific binding of [3H]prazosin to cYr-adrenergic receptors in rat brain membranes. In the course of isolation, CDS was shown to be neither the endogenous neurotransmitter (- )norepinephrine (NE) nor the guanyl nucleotide GTP which lowers the specific binding of cYz-agonists to the cus-adrenergic receptors. Clonidine cYrAdrenergic receptor Yohimbine Hypertension 1. INTRODUCTION oblongata [lo], prompted us to look for an en- dogenous clonidine-like substance in the brain. The wide-spread interest in m-adrenergic agonists is mostly due to their clinical application as antihypertensive drugs. Clonidine, guanabenz, 2. EXPERIMENTAL guanadrel, labaz, guanoxan and tramazoline are but a few representatives of numerous imidazoline 2.1. Chemicals and guanido-containing az-agonists (review [3H]Clonidine (25.5 Ci/mmol; Ci = 3.7 x 10” [l-4]). Their potent antihypertensive activity becquerels), [3H]prazosin (40 Ci/mmol), [3H]yo- results from stimulation of cuz-adrenergic receptors himbine (80 Ci/mmol), [3H]NE (24.6 Ci/mmol) in the central nervous system (CNS).
    [Show full text]
  • Caco-2: Predicting Drug Permeability and Relationship with COVID-19 Infected Caco-2 Cells Clifford Fong
    Caco-2: Predicting drug permeability and relationship with COVID-19 infected Caco-2 cells Clifford Fong To cite this version: Clifford Fong. Caco-2: Predicting drug permeability and relationship with COVID-19 infected Caco-2 cells. [Research Report] Eigenenergy Adelaide South Australia. 2021. hal-03147823 HAL Id: hal-03147823 https://hal.archives-ouvertes.fr/hal-03147823 Submitted on 21 Feb 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Caco-2: Predicting drug permeability and relationship with COVID-19 infected Caco-2 cells Clifford W. Fong Eigenenergy, Adelaide, South Australia, Australia. Email: [email protected] Keywords: Caco-2, drug cellular permeability, passive transcellular and paracellular diffusion, active transport, COVID-2019 or SARS-CoV-2; ACE2 receptor binding, spike serine proteases, pro S-RBD, TMPRSS2, M , IC50, host cell membrane fusion or endocytosis, translatome and proteome proteomics, linear free energy relationships, HOMO-LUMO; quantum mechanics; Abbreviations: Structure activity relationships SAR, ΔGdesolv,CDS
    [Show full text]